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ABSTRACT
Serum alkaline phosphatase (ALP), a gross marker of bone turnover, has been reported to be
elevated after menopause, a period characterized by hallmark increases in follicle-stimulat-
ing hormone (FSH). Whether the ALP rise coincides with the perimenopausal transition when
changes in FSH, estrogen levels, and menstrual cycles are first apparent is not known. The
purpose of this cross-sectional study was twofold: (1) to characterize the influence of the peri-
menopausal transition on ALP activity and (2) to correlate ALP activity with more precise
markers for bone, osteocalcin (OC), and vitamin K status assessed with undercarboxylated
osteocalcin (ucOC). Thirty-eight studies of hourly FSH were conducted on cycle day 6 of the
follicular phase in perimenopausal women volunteers, aged 40–54 years (mean body mass in-
dex [BMI] 5 24.2 6 0.5). Mean FSH was used to define the perimenopausal stage (early peri-
menopausal, mean FSH # 15 IU/L, n 5 27; late perimenopausal, mean FSH . 15 IU/L, n 5 11).
As expected, late perimenopausal women had irregular and longer menstrual cycles, lower
estradiol (E2) and estrone (E1) levels, and a lower frequency of ovulations vs. the early group.
ALP was higher (76.5 6 8.3 vs. 58.3 6 2.7 IU/L, p 5 0.045) compared with the early peri-
menopausal group. In a subsample (n 5 10), OC was associated with ALP (r 5 0.69, p , 0.03),
FSH was positively related to ucOC concentrations (r 5 0.7, p , 0.03), and women with E1 con-
centrations , 40 pg/ml had double the percentage of ucOC compared with those where E1
was . 40 pg/ml (46.3% 6 6.6% vs. 22.0% 6 3.1%, p , 0.006). Clinical markers of the peri-
menopause are associated with a nonspecific but inexpensive marker of enhanced bone
turnover (i.e., higher ALP) and correlate well with more precise markers of bone activity.
These findings suggest that health-promotion strategies for preserving bone should be insti-
tuted well before the last menstrual period.
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INTRODUCTION
THE RAPID BONE LOSS after menopause broughton by the dramatic decline in estradiol (E2)
has become one of the major reasons for treat-
ment of postmenopausal women with hormone
replacement therapy (HRT).1,2 Little is known,
however, about the nature and time course of the
menopause-mediated bone loss or whether pre-
emptive signs may exist in women approaching
their last menstrual cycles.
The years before menopause (perimenopause
transition) have only recently been studied but
are now considered to be a time of dramatic fluc-
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tuations in both gonadotropins and ovarian
steroids because of the diminished influence of
the ovarian follicular reserve and, thus, loss of
tight negative feedback, which is responsible for
the regular cyclicity of the menstrual cycle.3,4 In
response to rising follicle-stimulating hormone
(FSH) levels, the ovary intensifies its production
of estrogen despite a decline in the number of fol-
licles, and episodes of hyperestrogenism have
been reported in the perimenopause.4
A number of bone biomarkers in both blood
and urine have been used to assess bone turnover
in the menopause, with varying levels of preci-
sion.5–7 Although state-of-the-art assays have
been developed that identify the isoenzyme bone-
specific (ALP), these tests are expensive and sel-
dom are included in a routine medical examina-
tion. Healthy women are more likely to have a
measure of serum ALP (a less specific marker of
osteoblast activity). A rise in serum ALP has been
associated with decreased bone mineral density
in postmenopausal women (mean age 59.1 6 0.3
years).8
Only a few studies to date have examined the
relationship between markers of early reproduc-
tive aging (i.e., prior to menopause) and bone
function. Slemenda et al.9 reported significant
bone loss in irregularly cycling perimenopausal
women in a longitudinal, 3-year study. However,
the significance of these findings is not clear be-
cause data from the perimenopausal subjects
were combined with data from postmenopausal
women to predict rate of bone loss in order to
limit the impact of occasional high estrogen mea-
surements and low bone loss rates.
In a cross-sectional study of bone-related vari-
ables in women at different stages of the peri-
menopausal transition, a marked elevation of ALP
was present only in subjects with FSH values
.40 IU/L.10 Perimenopausal women with FSH
values between 20 and 40 IU/L showed essen-
tially similar concentrations to premenopausal
subjects. In this study, single measures of FSH
were obtained at random on the day of the clinic
visit and not drawn at an equivalent phase in the
menstrual cycle, thus raising questions about the
reliability of the gonadotropin characterization.
Moreover, retrospective recall in this and other
studies has been the only method used to assess
cycle length. Thus, the current understanding of
how the dynamic hormone changes during the
perimenopause relate to bone turnover remains
obscure.
To clarify the relationship between reproduc-
tive aging prior to menopause and bone loss, we
undertook a cross-sectional study of selected
bone biomarkers in perimenopausal women us-
ing an intensive blood-sampling protocol to more
precisely define reproductive hormones during
the early follicular phase and prospective chart-
ing to monitor menstrual cycle length. We hy-
pothesized that the measurement of serum ALP,
an inexpensive and commonly obtained labora-
tory test in clinical practice, may have some util-
ity for monitoring perimenopausal bone activity.
Osteocalcin (OC), a bone protein secreted by
osteoblasts, is a new specific biomarker of bone
turnover.11 The level of OC that would indicate
bone turnover in the postmenopause is not well
defined, as osteoporotic women have values that
extend throughout and just beyond the normal
range.12 Moreover, lack of a standardized com-
mercial assay complicates comparison of concen-
trations among studies.13
Undercarboxylated osteocalcin (ucOC) is a pre-
cise indicator of vitamin K status. It reflects vita-
min K’s role in carboxylating glutamic acid
residues on the protein that subsequently facili-
tates the binding of OC to hydroxyapatite in
bone.14–16 Both OC and ucOC can be measured
in the same assay.
Until now, OC assays were designed to moni-
tor supraphysiological concentrations in disease
states. In addition, older assays were limited by
their inability to distinguish the intact molecule
from fragments.17 Recently, a new assay specific
for the intact protein has been developed. As a
secondary aim of this study, we set out to estab-
lish the feasibility of using a modified assay spe-
cific for the intact OC protein to measure physio-
logical concentrations present in healthy women.
The undercarboxylated form was also examined
for changes during the climacteric years.
MATERIALS AND METHODS
Before initiation of the study, approval of the
clinical protocol was obtained from the Univer-
sity of Michigan Hospitals Institutional Review
Board (IRB) for use with human subjects. All vol-
unteers provided written informed consent. This
study was undertaken as part of a larger study of
the effects of HRT on the neuroreproductive axis
of perimenopausal women (NIH grant NUR01
01373, N. Reame, P.I.).
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Subjects
At the time of recruitment, 37 subjects met the
following eligibility criteria: aged 40 or older, in-
tact uterus and ovaries, a screening body mass in-
dex (BMI) of 20–30 kg/m2, a spontaneous men-
strual cycle within the preceding 6 months, a
history of normal menstrual cycles and at least
one pregnancy carried to term, normal endocrine
screen, no current medical or psychiatric illness,
no current use of oral contraceptives, no preg-
nancy or breastfeeding in the past 6 months, and
no current history of dieting, excessive exercise,
or alcohol consumption. One normal cycling sub-
ject was studied again 38 months later when she
was experiencing irregular cycles, yielding a to-
tal of 38 studies. For the substudy of OC and
ucOC, values from 1 subject (postmenopausal)
whose last menstrual cycle was 18 months prior
to the study was included for comparison with 9
perimenopausal subjects.
Study protocol
Subjects were admitted between cycle days 4
and 8 to the outpatient division of the General
Clinical Research Center of the University of
Michigan Hospitals for an 8-hour intensive
blood-sampling protocol (0900–1700 hours). To
assess general health status, subjects underwent
a psychosocial and medical health interview.
They also kept a daily diary of menstrual symp-
toms/bleeding and medication usage for up to 45
days. In all subjects, the results of screening stud-
ies for hemoglobin, hematocrit, liver function, in-
sulin, glucose, and serum cholesterol were in the
normal range for healthy volunteers after an
overnight fast.
During the 8-hour study, blood samples were
obtained through an indwelling intravenous (i.v.)
forearm catheter every 10 minutes to assess pul-
satile luteinizing hormone (LH) secretion, hourly
for FSH measures, and every 4 hours for E2 and
progesterone (P) determinations. A fasting sam-
ple of blood was drawn at 0900 hours (just prior
to the 8-hour sampling regimen) for determina-
tion of serum ALP, OC, ucOC, prolactin (PRL),
total testosterone (T), free T, estrone (E1), dehy-
droepiandrosterone sulfate (DHEAS), serum cal-
cium, phosphate, albumin, thyroid-stimulating
hormone (TSH), thyroxine (T4), total triiodothy-
ronine (T3) and liver enzymes, alanine amino-
transferase (ALT), and aspartate aminotrans-
ferase (AST). Three single blood draws were
collected at 1-week intervals following the follic-
ular phase study day for measurement of E2 and
P to determine the ovulatory status of the study
cycle.
Assays
Reproductive Hormone Assays. Plasma E2 (assay
sensitivity 5 pg/ml) and P (assay sensitivity 0.2
ng/ml) were measured using radioimmunoassay
(RIA) kits (Diagnostic Products Corp., Los Ange-
les, CA, and Radioassay Systems Laboratories,
Carson, CA). All samples for a subject were mea-
sured in the same assay. Intraassay and interas-
say coefficient of variation (CV) for E2 was 5.1%
and 9%, respectively. Intraassay and interassay
CV for P was 2.3% and 9.2%, respectively. Plasma
LH and FSH were determined by Delfia® fluoro-
metric immunoassay (IFMA) (Wallac Inc.,
Gaithersburg, MD). All samples were measured
in the same assay. Gonadotropin concentrations
are reported as international units per liter
(IU/L). The LH assay standard is calibrated
against the World Health Organization (WHO)
Second International Standard for pituitary LH
for immunoassay 80/552. FSH is calibrated
against the WHO Second International Reference
Preparation of human pituitary FSH/LH for
bioassay 78/549. For LH and FSH assays, the
limit of detection was 0.05 IU/L, and the interas-
say CV was 6.8% and 4.8%, respectively. For
analysis, values below assay sensitivity were as-
signed the value of assay sensitivity.
ALP Assay. Fasting serum ALP was analyzed by
the clinical ligand laboratory of the University of
Michigan Hospitals, using the dry slide method,
and read by a Vitros 900 Auto Analyzer (model
950)(Johnson & Johnson, Rochester, NY). The as-
say sensitivity is 20 IU/L, and the CV is 4.5%.
OC and ucOC Assay. OC was measured using a
modification of a previously validated immuno-
radiometric assay (N-tact® Osteo SP) (Incstar,
Stillwater, MN) that measures the intact pro-
tein.13 Plasma OC and ucOC were measured in a
subset of subjects (n 5 10, the last 10 subjects
studied). OC was measured in untreated plasma.
For measurement of ucOC, 400 ml plasma sample
was mixed with 8 mg calcium phosphate tribasic
(Mallinkrodt, Paris, KY) in micro-Eppendorf
tubes, mixing end-over-end for 30 minutes at 4°C
and centrifuging at 700g for 20 minutes at 4°C
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(protocol modified from J. Suttie, University of
Wisconsin-Madison). The ucOC was measured in
the supernatant. This treatment allows separation
of carboxylated and undercarboxylated species.
The assay modification involved extension of
the standard curve from 1.5 ng/ml down to 0.20
ng/ml. All samples were run in two assays, with
OC and ucOC for a given individual run in the
same assay in duplicate. Kits shipped from the
company within 5 days of iodination were used
for the two assays. Sample volume size used in
the assay was 100 ml per tube. Quality control
(QC) checks included a perimenopausal plasma
sample and a low control (human osteocalcin)
provided with the kit, both treated with calcium
phosphate tribasic (as described). The intraassay
CV for the perimenopausal QC (average 0.72
ng/ml, n 5 2) was 2.7%. The interassay CV for
the low control QC (average 0.775 ng/ml, n 5 2)
was 1.3%.
Assay sensitivity (2 standard deviations [SD]
of buffer control) for the two assays analyzed
was 0.09 ng/ml. Plasma samples from a peri-
menopausal and a postmenopausal volunteer
were diluted parallel to the standard curve in
this modified version (slopes: standard 1.09 6
0.018; perimenopausal 1.11 6 0.03; postmeno-
pausal 1.11 6 0.017). Recovery of serial dilu-
tions of kit standard and perimenopausal and
postmeno-pausal samples averaged 74%–119%.
Intraassay and interassay CV averaged 6.8%
and 9.1%, respectively.
Data analysis
Definition of Study Groups. To examine the ef-
fects of reproductive aging, subjects were initially
grouped as premenopausal (regular menstrual
cycles, no menopausal complaints, FSH # 15
IU/L, n 5 14), or perimenopausal (symptomatic
women with irregular cycles). This latter group
was further divided into an early (n 5 13) and
late (n 5 11) perimenopausal group according to
an FSH value of 15 IU/L. This value has been
used to define study groups in other studies of
perimenopausal bone loss and is associated with
low pregnancy rates in infertile patients.18 Be-
cause the normally cycling and early peri-
menopausal groups did not differ in BMI (23.4 6
0.5 vs. 24.5 6 0.7 kg/m2, respectively, p 5 NS) or
FSH (10.1 6 0.8 vs. 8.5 6 1.2 IU/L, respectively,
p 5 NS), E2 (47.9 6 7.3 vs. 95.8 6 20.5 pg/ml, re-
spectively, p 5 NS), and ALP (59.7 6 2.9 vs.
56.8 6 4.8 IU/L, respectively, p 5 NS) concentra-
tions, they were combined for all further analy-
ses (n 5 27) and are referred to as the early peri-
menopausal group.
Statistical Analysis. Physiological data are pre-
sented as mean 6 SE. Mean values of FSH, LH,
E2, and P were determined from the serial values
obtained across the 8-hour daytime sampling in-
terval during the follicular phase study. To ad-
just for differential binding of calcium by vary-
ing albumin levels, each subject’s serum total
calcium/albumin ratio was proportionally cor-
rected to a standard albumin level of 4.2 g/dl, us-
ing the method of Garton et al.19 The percent of
undercarboxylated osteocalcin (% ucOC) is the
calculated value:
%ucOC 5 3 100
The distribution of physiological values was
explored for normality. Where appropriate data
transformation was used for skewed distribu-
tions (e.g., logarithmic transformation for sex
steroid data, reciprocal transformation for ALP),
transformation did not change the outcome of the
results, and the transformation data are not re-
ported. Correlation analysis was performed us-
ing Pearson r test, and comparison between
groups was made using Fisher’s exact test (for fre-
quencies), independent sample t test, or Mann
Whitney U test. In two separate subanalyses on
% ucOC and estrogen status, subject data were
grouped by a cutoff of 20 pg/ml for E2 and 40
pg/ml for E1, based on reports of bone loss at
these concentrations.9 p values were derived us-




At the time of the study, 31 of the 37 subjects
(84%) had experienced their most recent men-
strual period within the past 3 months. In 5 oth-
ers (13%), the last menstrual period was within
the past 5 months, and in 1 subject (3%) the last
menses was 9 months earlier. Of the 38 menstrual
cycles assessed, 25 (66%) were ovulatory, as de-





Table 1 lists the clinical characteristics of the
two groups of women, early perimenopausal
(FSH # 15 IU/L) and late perimenopausal
(FSH . 15 IU/L) during the follicular phase
study. There were no significant differences be-
tween groups for age or body size characteristics.
As expected, the late perimenopausal group had
higher mean gonadotropin concentrations (p ,
0.001), lower plasma E2 levels (p 5 0.006), and
lower E1 levels (p , 0.05).
FSH concentration had a significant effect on
mean cycle length (p , 0.01); the positive corre-
lation was significant (r 5 0.66, p , 0.001). Early
perimenopausal women (FSH range 4–15 IU/L)
had cycle lengths ranging from 15 to 63 days. In
contrast, menstrual bleeding intervals ranged
from 27 to 161 days in the late perimenopausal
group (FSH range 20–98 IU/L). Anovulatory cy-
cles were present in 73% of the late peri-
menopausal women, a higher rate than observed
in the early perimenopausal group (28%, p ,
0.003).
No group differences were observed for PRL or
DHEAS concentrations or in thyroid function or
liver enzyme activity (ALT, AST). The expected
effects of the perimenopause on T concentrations
were observed. Serum phosphate did not differ
between groups, but serum calcium, when cor-
rected for a serum albumin of 4.2 g/dl, was sig-
nificantly lower in the late perimenopausal group
(9.5 6 0.1 vs. 9.8 6 0.1 mg/dl, p 5 0.03).
Reproductive aging and serum markers of 
bone health
All subjects had ALP concentrations in the nor-
mal range for this enzyme, 30–130 IU/L. In the
late perimenopausal group, the concentration of
ALP was higher than in the early perimenopausal
group (76.5 6 8.3 vs. 58.3 6 2.7 IU/L, p , 0.05)
(Fig. 1). Correlations between the measures of re-
productive aging and bone metabolism are shown
in Table 2. ALP concentrations were correlated
with higher mean FSH (p 5 0.01) and higher mean
LH (p , 0.001) on day 6 6 2 of the menstrual cy-
cle. Additionally, there was a trend for higher ALP
levels with longer cycle lengths (p 5 0.06). An as-
sociation between ALP and E2 concentrations was
not observed (p 5 0.40). Serum calcium was pos-
itively associated with age (p , 0.04). The nega-
tive association between serum calcium and FSH
was not significant (p 5 0.09).
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TABLE 1. CLINICAL CHARACTERISTICS OF PERIMENOPAUSAL WOMEN BY SCREENING FSH
Early perimenopause Late perimenopause
FSH # 15 IU/L FSH # 15 IU/L
(n 5 27) (n 5 11) p value
Age (years) 46.3 6 0.8a 48.6 6 0.9 0.1b
BMI (kg/m2)c 23.9 6 0.4 24.7 6 1.3 0.5
Menstrual cycle length (days) 29.6 6 2.3 76.0 6 15.3 0.0001b
FSH (IU/L) 9.3 6 0.7 39.4 6 6.6 ,0.001
LH (IU/L) 5.8 6 0.7 23.9 6 4.7 ,0.001
E2 (pg/ml) 71.0 6 11.4 27.0 6 7.1 0.006
E1 (pg/ml) 73.4 6 9.7 48.4 6 9.9 ,0.05
P (ng/ml) 0.3 6 0.08 0.2 6 0.006 0.4
OV1 22/27 (82%) 3/11 (27%) ,0.003d
Prolactin (ng/ml) 8.3 6 0.7 6.1 6 0.8 0.06
DHEAS (ng/ml) 971.6 6 94.1 977.0 6 214.5 ,1.0
Total T (ng/ml) 0.3 6 0.02 0.2 6 0.04 ,0.02
Free T (pg/ml) 0.4 6 0.08 0.9 6 0.2 0.03
TSH (mU/ml) 2.1 6 0.3 2.8 6 0.4 ,0.3
T4 (mg/dl) 7.3 6 0.3 6.5 6 0.4 0.1
T3 (ng/dl) 134.0 6 4.6 121.0 6 5.2 0.1
ALT (U/L) 26.0 6 2.2 25.3 6 3.0 ,0.9
AST (U/L) 25.4 6 1.6 24.5 6 2.1 0.7
aValues are mean 6 SE. t tests reported unless otherwise indicated.
bMann Whitney U test.
cBMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; E1, estrone; P,
progesterone; OV1, midluteal progesterone rise of $4 ng/ml; DHEAS, dehydroepiandrosterone sulfate; T, testos-
terone; TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine; ALT, alanine aminotransferase; AST,
aspartate aminotransferase.
dFischers Exact Test
In a subsample (n 5 10), serum ALP was pos-
itively associated with OC (r 5 0.69, p , 0.03)
(Fig. 2) and showed a statistical trend with ucOC
(r 5 0.59, p 5 0.07). FSH was positively related to
ALP (r 5 0.78, p , 0.007) and ucOC (r 5 0.7, p ,
0.03) and showed a trend with OC (r 5 0.56, p 5
0.09).
The % ucOC was higher in the group of women
with E1 concentrations ,40 pg/ml compared with
those with concentrations .40 pg/ml (46.3% 6
6.6% vs. 22.0% 6 3.1%, low E1 vs. higher E1, p 5
0.006). Women with E1 concentrations ,40 pg/ml
also had E2 concentrations ,20 pg/ml, represen-
tative of a low estrogen environment overall. A
trend for higher % ucOC was found in the group
of women with E2 concentrations ,20 pg/ml
compared with those with concentrations .20
pg/ml (40.5% 6 7.7% vs. 22.8% 6 3.7%, low E2 vs.
higher E2, p 5 0.07).
DISCUSSION
The climacteric encompasses the complete
span of reproductive aging, generally considered
to begin with the decline in fertility after the age
of 35. In a woman’s early 40s there is an increase
in mean FSH concentrations and LH pulsatility
before any reduction in estrogen or P.20 Episodes
of hyperestrogenism may also occur secondary to
the elevated FSH and accelerated follicular de-
velopment.4 Thereafter, there is a dramatic de-
cline in the production of both E2 and E1 and no-
table declines in T and androstenedione.21 The
stage of the climacteric where bone turnover ac-
celerates has not been conclusively established.
Several investigators have suggested that accel-
erated bone turnover commences prior to the ac-
tual menopause, but methodological weaknesses
have limited the significance of their find-
ings.9,10,19,22–24 These limitations include the use
of single blood samples to assess sex steroid and
gonadotropin concentrations, failure to synchro-
nize the timing of blood draws in relation to the
menstrual cycle, and the use of heterogeneous
study samples poorly defined for menopausal
status.
To better characterize the relationship between
a gross marker of bone turnover (ALP) and a more
precise indicator of bone activity (OC and ucOC)
with reproductive aging, we used serial measures
to assess sex steroids and gonadotropins in the
early follicular phase of the menstrual cycle. In
this way, women were classified into early or late
perimenopausal groups based on the mean of 9
hourly FSH concentrations on cycle day 6. The use
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FIG. 1. Comparison of fasting serum ALP for early peri-
menopausal (peri) women with FSH # 15 IU/L (n 5 27)
vs. late perimenopausal women with FSH . 15 IU/L (n 5
11) in the early follicular phase (menstrual cycle days 4–8).
Late perimenopausal women with FSH . 15 IU/L had
significantly higher concentrations of serum ALP. *t 5
2.08; p , 0.05.
TABLE 2. PEARSON CORRELATIONS FOR ALP OR CALCIUM WITH AGE AND
MARKERS OF REPRODUCTIVE AGING: FSH, LH, CYCLE LENGTH, AND E2 (n 5 38)
Age FSH LH Cycle length E2
ALP 0.15 0.41 0.56 0.31 20.14
( p 5 0.01) ( p , 0.001) ( p 5 0.06)
Calciuma 0.34 20.28 20.08 20.14 0.22
( p , 0.04) ( p 5 0.09)
aCorrected for serum albumin of 4.2 g/dl.
of frequent blood sampling to detect dynamic FSH
secretion permits a more precise determination of
the true perimenopausal state. With this intensive
sampling technique, we were able to detect dif-
ferences in ALP concentrations associated with an
FSH value .15 IU/L. This level of FSH has been
shown to be indicative of early reproductive ag-
ing and is much lower than that observed in prior
studies of menopausal effects on bone turnover
when single estimates of FSH were obtained.9,10,23
The higher concentrations of ALP in our late per-
imenopausal group would seem to be unrelated to
chronological age, given the similar ages of the two
study groups. Moreover, in the early peri-
menopausal group, the normally cycling women
were significantly younger (mean age 43.2 6 0.7 vs.
49.5 6 0.8 years, p , 0.001) than those with irregu-
lar cycles, but ALP levels were similar. Thus, there
appears to be no age-related influence on ALP
function during the midlife years.
To what extent the observed elevation in ALP
in women with an FSH value .15 IU/L is asso-
ciated with clinical manifestations of bone loss is
not known, as bone density measures were not
obtained in this study. Future studies should in-
corporate a longitudinal design across the peri-
menopausal transition to assess bone biomarkers
and their relation to bone density.
Previous reports have been inconsistent about
the relationship between bone turnover markers
or bone density and E2. Some have reported a neg-
ative relationship between bone biomarkers (OC)
and E2,9 whereas others have found no relation-
ship between bone density and E2.24 Despite sig-
nificantly lower levels of E2 in the late peri-
menopausal group, we found no relationship
between day 6 mean E2 and ALP (r 5 20.14, p 5
0.40) when data from the entire sample were as-
sessed. In this study, as in previous studies, E2 was
determined on a single day, which may have ham-
pered our ability to determine the more chronic es-
trogen environment and the true relationship to
ALP activity. Additionally, a single menstrual cy-
cle differs in length from the average remodeling
cycle of bone (approximately 4–8 months)25,26 and,
therefore, may not be capturing the total activity
that gave rise to ALP concentrations at one time.
Using a new IRMA assay for intact protein (N-
tact), we also demonstrated that OC is detectable,
albeit at low concentrations, in healthy peri-
menopausal women. By this method, we were
able to show for the first time that FSH is related
to ucOC concentrations. The biochemical influ-
ence of the undercarboxylated species of OC is
currently not known, but ucOC has been reported
to predict the risk of hip fracture among elderly
women.27 Moreover, ucOC concentrations were
higher in postmenopausal women than in cycling
women in a study where menopause was defined
by recall of last menstrual period.14 Additionally,
in this study, ucOC elevations occurred in con-
cert with elevations in ALP, although not at con-
ventional levels of significance. Thus, reproduc-
tive aging may be important in the phenomenon
of elevated ucOC after menopause.
This study also reports a possible link between
estrogen status and ucOC. Of particular interest
is that E1 (the predominant circulating estrogen
after menopause) was a better discriminator than
E2 (the dominant estrogen before menopause) in
determining the degree to which OC was under-
carboxylated. In our very small sample of cli-
macteric women (n 5 10), those with E1 concen-
trations ,40 pg/ml had more than a twofold
increase in % ucOC. The role that estrogen may
have in the carboxylation of the bone protein is
unknown and needs elucidation. Given the rela-
tively higher free concentrations of E1 vs. E2 dur-
ing the postmenopausal years,28 the bioactive in-
fluence of E1 on postmenopausal bone may be
underestimated.29
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FIG. 2. Relationship between ALP and OC concentra-
tions at 0900 hours (r 5 0.69, p , 0.03, n 5 10). Menstrual
cycle days 4–8 for the perimenopausal women and ran-
dom day for the postmenopausal woman with 18 months
of amenorrhea.
CONCLUSIONS
The findings from this cross-sectional study
performed in a group of healthy perimenopau-
sal women with well-characterized gonadotropin
and sex steroid levels confirm that signs of re-
productive aging (elevated gonadotropins and
prolonged cycles) are associated with elevated
ALP concentrations and, in turn, with OC, a
more specific bone marker. To confirm the clin-
ical significance of this finding, future studies
should include measures of bone density. Mea-
surement of ALP in healthy perimenopausal
women offers a nonspecific but inexpensive
marker of bone loss that is commonly deter-
mined as part of the physical examination in
midlife women. Furthermore, these data suggest
that health-promotion strategies for preserving
bone should be instituted well before the last
menstrual period.
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